# Radiotherapy after Oesophageal Cancer Stenting (ROCS) study

Submission date 04/07/2012	<b>Recruitment status</b> No longer recruiting	<ul><li>[X] Prospectively registered</li><li>[X] Protocol</li></ul>
Registration date 10/07/2012	<b>Overall study status</b> Completed	<ul> <li>[] Statistical analysis plan</li> <li>[X] Results</li> </ul>
Last Edited 28/02/2023	<b>Condition category</b> Cancer	<ul> <li>Individual participant data</li> </ul>

### Plain English summary of protocol

https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-radiotherapy-oesophageal-cancer-difficulty-swallowing-rocs

## **Contact information**

**Type(s)** Scientific

**Contact name** Dr Douglas Adamson

### **Contact details**

Ward 32 Ninewells Hosptial Dundee United Kingdom DD1 9SY

### Type(s)

Public

**Contact name** Ms Martina Svobodova

### **Contact details**

Centre for Trials Research (CTR) College of Biomedical and Life Sciences Cardiff University 6th Floor, Neuadd Meirionnydd Heath Park Cardiff United Kingdom CF14 4YS +44(0)29 20687463 ROCS@cardiff.ac.uk

## Additional identifiers

EudraCT/CTIS number

**IRAS number** 

ClinicalTrials.gov number NCT01915693

Secondary identifying numbers HTA 10/50/49, WCTU030

## Study information

#### Scientific Title

Palliative radiotherapy in addition to self-expanding metal stent for improving dysphagia and survival in advanced oesophageal cancer: Radiotherapy after Oesophageal Cancer Stenting (ROCS) study

#### Acronym

ROCS

### **Study objectives**

Radiotherapy in addition to self-expanding metal stent (SEMS) placement improves patientreported dysphagia and increases time to progression in a patient population unable to undergo surgery.

More details can be found at http://www.nets.nihr.ac.uk/projects/hta/105049 Protocol can be found at http://www.nets.nihr.ac.uk/\_\_data/assets/pdf\_file/0009/81666/PRO-10-50-49.pdf

**Ethics approval required** Old ethics approval format

**Ethics approval(s)** Not provided at time of registration

### Study design

Two-arm open randomised phase III trial with a 1:1 randomisation ratio. A qualitative component in a sub-set of patients.

**Primary study design** Interventional

Secondary study design

### Randomised controlled trial

### Study setting(s)

Hospital

#### Study type(s) Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

### Health condition(s) or problem(s) studied

Oesophageal cancer requiring stent for relief of dysphagia

### Interventions

Arm A: Self-expanding metal stents (SEMS) (Control Arm) SEMS insertion will be undertaken in accordance with standard local protocols. Covered or partially covered metal stents will be used and the length type and mode of stent placement will be selected by the clinician. Insertion will occur within two weeks of randomisation.

Arm B: SEMS plus external beam radiotherapy (Intervention Arm)

External beam radiotherapy (EBRT) is routinely available at regional cancer centres across the UK. For palliation of dysphagia in oesophageal cancer, a radiotherapy course delivering a tumour absorbed dose of 20Gy in 5 fractions or 30Gy in 10 fractions within 4 weeks of SEMS insertion.

### Intervention Type

Other

Phase Not Applicable

### Primary outcome measure

Assess the impact of radiotherapy in addition to self-expanding metal stent (SEMS) placement on time to progression of patient-reported dysphagia in a patient population unable to undergo surgery.

### Secondary outcome measures

1. Assess the impact of combination treatment on core components of health related quality of life

2. Assess the impact of radiotherapy in addition to SEMS placement on overall survival

- 3. Measure morbidity associated with the interventions
- 4. Measure re-intervention rates

5. Assess the cost of the addition of radiotherapy to SEMS placement

### **Overall study start date**

01/10/2012

## Completion date

30/11/2018

## Eligibility

### Key inclusion criteria

1. Histological confirmation of oesophageal carcinoma excluding small cell histology

2. Not suitable for radical treatment (oesophagectomy or radical chemoradiotherapy) either because of patient choice or medical reasons

3. Dysphagia clinically assessed as needing stent as primary treatment of the dysphagia

4. Age 16 years or over

5. Discussion and treatment decision for SEMS placement made by an Upper GI multi-disciplinary team

6. Clinician assessment of ability to attend for radiotherapy

7. Expected survival of at least 12 weeks

8. Written informed consent

### Participant type(s)

Patient

Age group

Adult

**Sex** Both

**Target number of participants** 496

**Total final enrolment** 220

### Key exclusion criteria

- 1. Histology of small cell carcinoma type
- 2. Tumour length of greater than 12 cm
- 3. Tumour growth within 2 cm of the upper oesophageal sphincter
- 4. Endoscopic treatment of the tumour, other than dilatation, planned in the peri-stent period
- 5. Presence of a tracheo-oesophageal fistula
- 6. Presence of a pacemaker
- 7. Previous radiotherapy to the area of the proposed radiotherapy field
- 8. Planned endoscopic treatment of the tumour (e.g. laser) in the immediate peri-stenting period

9. Pregnancy

### Date of first enrolment

01/10/2012

Date of final enrolment 31/08/2018

## Locations

**Countries of recruitment** Scotland

#### United Kingdom

**Study participating centre Ward 32** Dundee United Kingdom DD1 9SY

### Sponsor information

**Organisation** Velindre NHS Trust (UK)

#### **Sponsor details**

Mrs Sarah Townsend Research & Development Office Velindre NHS Trust 3rd Floor 14 Cathedral Road Cardiff Wales United Kingdom CF11 9LJ

#### Sponsor type

Hospital/treatment centre

#### ROR

https://ror.org/05ntqkc30

### Funder(s)

**Funder type** Government

**Funder Name** NIHR Health Technology Assessment Programme - HTA (UK), 10/50/49

### **Results and Publications**

### Publication and dissemination plan

Not provided at time of registration

### Intention to publish date

30/03/2021

### Individual participant data (IPD) sharing plan

Not provided at time of registration

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<u>Protocol article</u>	protocol	22/10/2014		Yes	No
<u>Results article</u>	results	01/04/2021	22/02/2021	Yes	No
<u>Results article</u> <u>Plain English results</u>		01/05/2021	28/05/2021 28/02/2023	Yes No	No Yes